JP5619289B2 - Ｃ型肝炎ウイルス阻害剤 - Google Patents
Ｃ型肝炎ウイルス阻害剤 Download PDFInfo
- Publication number
- JP5619289B2 JP5619289B2 JP2013530121A JP2013530121A JP5619289B2 JP 5619289 B2 JP5619289 B2 JP 5619289B2 JP 2013530121 A JP2013530121 A JP 2013530121A JP 2013530121 A JP2013530121 A JP 2013530121A JP 5619289 B2 JP5619289 B2 JP 5619289B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- solvent
- minutes
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(*)(*1)C(*)(*)NC1c1ncc[n]1 Chemical compound CC(*)(*1)C(*)(*)NC1c1ncc[n]1 0.000 description 20
- DGGKXQQCVPAUEA-UHFFFAOYSA-N C(C1)C2NC1CCC2 Chemical compound C(C1)C2NC1CCC2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 1
- FZGIOGLBCYSAGS-WCSIJFPASA-N C(c(cc1)ccc1-c1c[nH]c(C2NCCC2)n1)Oc(cc1)ccc1-c1c[nH]c([C@H]2NCCC2)n1 Chemical compound C(c(cc1)ccc1-c1c[nH]c(C2NCCC2)n1)Oc(cc1)ccc1-c1c[nH]c([C@H]2NCCC2)n1 FZGIOGLBCYSAGS-WCSIJFPASA-N 0.000 description 1
- KIBWZPHNDYFRFZ-UHFFFAOYSA-N C=Cc1c(C(O)=O)nccc1 Chemical compound C=Cc1c(C(O)=O)nccc1 KIBWZPHNDYFRFZ-UHFFFAOYSA-N 0.000 description 1
- FRCRNJHHZXJLMJ-ABLWVSNPSA-N CC(C(O[C@@H](C)c1ccccc1)=O)c(cccc1)c1F Chemical compound CC(C(O[C@@H](C)c1ccccc1)=O)c(cccc1)c1F FRCRNJHHZXJLMJ-ABLWVSNPSA-N 0.000 description 1
- GJJYYMXBCYYXPQ-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)C1=O)=O Chemical compound CC(C)(C)OC(N(CCC1)C1=O)=O GJJYYMXBCYYXPQ-UHFFFAOYSA-N 0.000 description 1
- WYVJHHIVQNKMQT-UHFFFAOYSA-N CCNCC(c1ccc(COCc(cc2)ccc2C(CN)=O)cc1)=O Chemical compound CCNCC(c1ccc(COCc(cc2)ccc2C(CN)=O)cc1)=O WYVJHHIVQNKMQT-UHFFFAOYSA-N 0.000 description 1
- QVPBVAKLIWUEEJ-UHFFFAOYSA-N CN(C)C(C(O)=O)c1cnc(cccc2)c2c1 Chemical compound CN(C)C(C(O)=O)c1cnc(cccc2)c2c1 QVPBVAKLIWUEEJ-UHFFFAOYSA-N 0.000 description 1
- SKCUMFJFAWFXDL-UHFFFAOYSA-N CN(C)C1(Cc2ccccc2C1)C(O)=O Chemical compound CN(C)C1(Cc2ccccc2C1)C(O)=O SKCUMFJFAWFXDL-UHFFFAOYSA-N 0.000 description 1
- WSQJCEGRNUAEQD-JRTLPCBOSA-N CN(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(-c(cc2)ccc2-c(cc2)ccc2-c(cc2)ccc2-c2c[nH]c([C@H](CCC3)N3C([C@@H](c3ccccc3)N(C)C)=O)n2)c[nH]1)=O)c1ccccc1 Chemical compound CN(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(-c(cc2)ccc2-c(cc2)ccc2-c(cc2)ccc2-c2c[nH]c([C@H](CCC3)N3C([C@@H](c3ccccc3)N(C)C)=O)n2)c[nH]1)=O)c1ccccc1 WSQJCEGRNUAEQD-JRTLPCBOSA-N 0.000 description 1
- JCWUTEGWHABTTF-SECBINFHSA-N CN(C)[C@@H](C(O)=O)c(cccc1)c1F Chemical compound CN(C)[C@@H](C(O)=O)c(cccc1)c1F JCWUTEGWHABTTF-SECBINFHSA-N 0.000 description 1
- JCWUTEGWHABTTF-VIFPVBQESA-N CN(C)[C@H](C(O)=O)c1ccccc1F Chemical compound CN(C)[C@H](C(O)=O)c1ccccc1F JCWUTEGWHABTTF-VIFPVBQESA-N 0.000 description 1
- GOJLQSAREKTKPT-MRVPVSSYSA-N COC(N[C@@H](C(O)=O)c1ccccc1)=O Chemical compound COC(N[C@@H](C(O)=O)c1ccccc1)=O GOJLQSAREKTKPT-MRVPVSSYSA-N 0.000 description 1
- IAQVBFWXJXRRMU-INIZCTEOSA-N COC([C@H](C(CC1)CCC11OCCO1)NC(OCc1ccccc1)=O)=O Chemical compound COC([C@H](C(CC1)CCC11OCCO1)NC(OCc1ccccc1)=O)=O IAQVBFWXJXRRMU-INIZCTEOSA-N 0.000 description 1
- OOIJOKDKOOJZJS-BYPYZUCNSA-N C[C@@H](C(O)=O)NC(N(C)C)=O Chemical compound C[C@@H](C(O)=O)NC(N(C)C)=O OOIJOKDKOOJZJS-BYPYZUCNSA-N 0.000 description 1
- MPFWQXMMIIJDNP-LRDDRELGSA-N C[C@@H](CC[C@H]1c2ncc(-c(cc3)ccc3Br)[nH]2)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CC[C@H]1c2ncc(-c(cc3)ccc3Br)[nH]2)N1C(OC(C)(C)C)=O MPFWQXMMIIJDNP-LRDDRELGSA-N 0.000 description 1
- QEIFWXUIJHFGPI-IMJSIDKUSA-N C[C@@H]([C@@H](C(O)=O)NC(OC)=O)O Chemical compound C[C@@H]([C@@H](C(O)=O)NC(OC)=O)O QEIFWXUIJHFGPI-IMJSIDKUSA-N 0.000 description 1
- GFRABURJAGGVIU-SUMWQHHRSA-N C[C@@H](c1ccccc1)OC([C@@H](c(cccc1)c1F)N(C)C)=O Chemical compound C[C@@H](c1ccccc1)OC([C@@H](c(cccc1)c1F)N(C)C)=O GFRABURJAGGVIU-SUMWQHHRSA-N 0.000 description 1
- QEIFWXUIJHFGPI-DMTCNVIQSA-N C[C@H]([C@@H](C(O)=O)NC(OC)=O)O Chemical compound C[C@H]([C@@H](C(O)=O)NC(OC)=O)O QEIFWXUIJHFGPI-DMTCNVIQSA-N 0.000 description 1
- KFXVSKIKSXJAJS-UHFFFAOYSA-N Cc(cc(cc1)C(CBr)=O)c1Br Chemical compound Cc(cc(cc1)C(CBr)=O)c1Br KFXVSKIKSXJAJS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/050138 WO2012039717A1 (en) | 2010-09-24 | 2010-09-24 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013537905A JP2013537905A (ja) | 2013-10-07 |
| JP2013537905A5 JP2013537905A5 (https=) | 2013-11-14 |
| JP5619289B2 true JP5619289B2 (ja) | 2014-11-05 |
Family
ID=43037168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530121A Expired - Fee Related JP5619289B2 (ja) | 2010-09-24 | 2010-09-24 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2619195A1 (https=) |
| JP (1) | JP5619289B2 (https=) |
| CN (1) | CN103249730A (https=) |
| BR (1) | BR112013008148A2 (https=) |
| CA (1) | CA2812699A1 (https=) |
| EA (1) | EA201370078A1 (https=) |
| MX (1) | MX2013002927A (https=) |
| WO (1) | WO2012039717A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| EA020031B1 (ru) | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| AU2010274001A1 (en) | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
| CN102869657A (zh) | 2010-03-24 | 2013-01-09 | 沃泰克斯药物股份有限公司 | 用于治疗或预防黄病毒感染的类似物 |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US8859595B2 (en) | 2010-08-26 | 2014-10-14 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis C virus |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| AU2013217224B2 (en) | 2012-02-10 | 2017-04-06 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| ES2617863T3 (es) | 2012-06-04 | 2017-06-20 | Actelion Pharmaceuticals Ltd. | Derivados de bencimidazol-prolina |
| EA201500399A1 (ru) | 2012-10-10 | 2015-09-30 | Актелион Фармасьютиклз Лтд. | Антагонисты рецептора орексина, которые представляют собой производные [орто-би-(гетеро)арил]-[2-(мета-би-(гетеро)арил)пирролидин-1-ил]метанона |
| CA2902135A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| SI3077391T1 (sl) | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN113979962A (zh) | 2017-03-31 | 2022-01-28 | 先正达参股股份有限公司 | 杀真菌组合物 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CN113631560B (zh) | 2019-03-15 | 2025-02-18 | 麦迪穆有限责任公司 | 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物 |
| CN121335892A (zh) * | 2023-06-14 | 2026-01-13 | 阿雷克森制药公司 | 用于合成补体因子d抑制剂及其中间体的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| AU2003264038A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Combination pharmaceutical agents as inhibitors of hcv replication |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DE102004036971B4 (de) | 2004-07-30 | 2009-07-30 | Advanced Micro Devices, Inc., Sunnyvale | Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2010034721A (ja) * | 2008-07-28 | 2010-02-12 | Fujitsu Ltd | パケットキャプチャ装置，パケットキャプチャ方法およびパケットキャプチャプログラム |
| CA2750577A1 (en) * | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| US8796466B2 (en) * | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8138215B2 (en) * | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2010
- 2010-09-24 EA EA201370078A patent/EA201370078A1/ru unknown
- 2010-09-24 JP JP2013530121A patent/JP5619289B2/ja not_active Expired - Fee Related
- 2010-09-24 CN CN2010800703399A patent/CN103249730A/zh active Pending
- 2010-09-24 CA CA2812699A patent/CA2812699A1/en not_active Abandoned
- 2010-09-24 EP EP10761101.4A patent/EP2619195A1/en not_active Withdrawn
- 2010-09-24 MX MX2013002927A patent/MX2013002927A/es not_active Application Discontinuation
- 2010-09-24 BR BR112013008148A patent/BR112013008148A2/pt not_active IP Right Cessation
- 2010-09-24 WO PCT/US2010/050138 patent/WO2012039717A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013008148A2 (pt) | 2016-08-09 |
| CA2812699A1 (en) | 2012-03-29 |
| WO2012039717A1 (en) | 2012-03-29 |
| JP2013537905A (ja) | 2013-10-07 |
| EA201370078A1 (ru) | 2013-11-29 |
| MX2013002927A (es) | 2013-05-30 |
| CN103249730A (zh) | 2013-08-14 |
| EP2619195A1 (en) | 2013-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5619289B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5612660B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5612661B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5615352B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5697679B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5785189B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5847284B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5611959B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5632910B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5805763B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5558557B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| CN102177141B (zh) | 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑 | |
| JP5596861B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| US20110237636A1 (en) | Hepatitis C Virus Inhibitors | |
| JP2010527373A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2011511840A (ja) | Ｃ型肝炎ウイルス阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130829 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130829 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140819 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140821 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140916 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5619289 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |